source
- Venture debt becomes central financing option for late-stage European biotechBioSpace’s Denatured podcast recently featured Jennifer McMahon of Seroba and Joey Mason of Claret Capital discussing the growing role of venture debt in European biotech. The guests explained tha…
- Roche signs near-$1 billion partnership with Chinese biotech Defand on degrader therapiesRoche has entered into a new collaboration with Defand, a relatively unknown biotech based in Hangzhou, China. The agreement is the fourth China-focused deal the Swiss drugmaker has signed since Au…